Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer

Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada

KKR to invest in life sciences firm Catalio Capital Management

Investment is additive to KKR’s existing health care growth strategy

Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery

Three block copolymers added to RESOMER portfolio of bioabsorbable polymers

Granules India receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules

Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)

Clariant launches new range of excipients to improve stability and solubility of APIs at CPHI Barcelona

New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral

Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr

Profit after tax (before exceptional items) up 23% to Rs 215 crores

Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes

Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually

USFDA inspection at Biocon Biologics' manufacturing facility in Johor, Malaysia

Shilpa Medicare Unit IV, Jadcherla has cleared TGA, Australia GMP inspection

This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years

Glenmark receives ANDA approval for Apremilast Tablets

Glenmark's current portfolio consists of 188 products authorized for distribution in the US